BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC has launched mometasone furoate nasal spray, which marks the company’s first pharmaceutical product in spray form.

Amneal said its mometasone furoate product, a generic version of Nasonex, is available in 50 mcg/spray strength and packaged in a white, high-density, polyethylene bottle fitted with a white, metered-dose, manual spray pump and turquoise cap. Each 17-gram bottle delivers 120 sprays.

Manufactured in Branchburg, N.J., the product began shipping this month through wholesalers, distributors and directly to the trade.

“This launch marks a new milestone for us,” stated Jim Luce, executive vice president of sales and marketing at Amneal. “As the first nasal spray product from Amneal, it stands as yet another example of how we continue to expand into new and more complex dosage forms. Metered dose inhalers, transdermal patches and chewable tablets are just a few of those in the pipeline that we are excited to bring to market, significantly expanding our product offering.”

Mometasone furoate is indicated for the treatment of nasal symptoms from seasonal or year-round allergies, including congestion, sneezing and runny nose.

Annual U.S. sales of branded and generic mometasone furoate nasal spray totaled $653 million for the year ended in December, according to IMS Health data reported by Amneal.